Ocriplasmina

Ocriplasmina Uses, Dosage, Side Effects, Food Interaction and all others data.

Ocriplasmina is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmina is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.

Table Of contents

• Ocriplasmina
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Ocriplasmina
Generic	Ocriplasmin
Ocriplasmin Other Names	Microplasmin, Microplasmin (synthetic human), Ocriplasmin, Ocriplasmina, Recombinant human microplasmin
Type
Formula	C1214H1890N338O348S14
Weight	27250.0 Da
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Ocriplasmina is a proteolytic enzyme used to treat symptomatic vitreomacular adhesion by dissolving the protein matrix responsible for the adhesion between the vitreous and macula.

Ocriplasmina is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.

Ocriplasmina is also used to associated treatment for these conditions: Symptomatic Vitreomacular Adhesion

How Ocriplasmina works

Ocriplasmina has proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (VRI) (e.g. laminin, fibronectin and collagen), thereby dissolving the protein matrix responsible for the vitreomacular adhesion (VMA).

Toxicity

The most commonly reported reactions (≥ 5%) in patients treated with ocriplasmin were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.

Food Interaction

No interactions found.

Elimination Route

Because of the small dose administered (0.125 mg), ocriplasmin is not expected to be in the systemic circulation following injection. Within 30 minutes after injection, levels of ocriplasmin in the vitreous are 12 mcg/mL. 24 hours after injection, levels in the virtreous are 0.5 mcg/mL

Innovators Monograph

You find simplified version here Ocriplasmina